Browsing Tag
PRKAG2 syndrome
2 posts
Atrium Therapeutics (Nasdaq: RNA) Q1 results show cash runway and clinical urgency behind precision cardiology bet
Atrium has cash and RNA ambition. The harder test is whether heart-targeted delivery can turn rare cardiomyopathy science into clinical proof.
Can RNA medicines really reach the heart? Atrium Therapeutics (Nasdaq: RNA) is putting $270m on the line
Atrium Therapeutics launches with $270 million to advance RNA medicines for rare genetic cardiomyopathies. Find out why investors are watching closely.